Enfortumab Plus Pembrolizumab Extends Bladder Cancer Survival
A phase 3 trial reports sustained overall survival benefit over chemotherapy in previously untreated advanced urothelial carcinoma at 3.5-year follow-up.
Updated on Nov. 18, 2026 in Cancer

Enfortumab vedotin plus pembrolizumab showed a sustained overall survival benefit over chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma, based on data with a cutoff of October 6, 2025. Median follow-up in the trial was 42.8 months, with 886 patients randomized 1:1 between the two treatment arms.
Why it matters
The findings extend the survival advantage of the combination regimen over standard chemotherapy for a difficult-to-treat bladder and urinary tract cancer. The trial reported no new safety signals for the regimen during the extended follow-up.
Among responding patients, 45.1% in the combination arm achieved a complete response versus 32.8% in the chemotherapy arm, and 66.2% of those with confirmed complete response had first reached a partial response. Whether these durable responses persist beyond the reported follow-up period remains unstated in the trial data.
The players
American Society of Clinical Oncology (ASCO)
ASCO is a professional organization of oncologists that publishes abstracts and hosts major annual scientific meetings on cancer research.
The details
The trial randomized 886 patients to receive enfortumab vedotin 1.25 mg/kg on days 1 and 8 of each 3-week cycle plus pembrolizumab 200 mg, or to gemcitabine with cisplatin or carboplatin. Treatment continued until disease progression, toxicity, or the maximum number of cycles.
Timeline
August 8, 2024: Data cutoff for the complete response analysis.
October 6, 2025: Data cutoff for the 42.8-month median follow-up.
November 18, 2026: Abstract published on asco.org.
Health Landscape
The results add longer-term survival data to a first-line regimen that is being compared against the long-standing gemcitabine plus cisplatin or carboplatin standard used in this trial. The regimen's sustained survival advantage over that chemotherapy control arm at 3.5 years is the central point of comparison.
For patients with advanced urothelial carcinoma, the trial data suggest a longer overall survival period with this combination than with chemotherapy. The reported safety profile showed no new signals during extended follow-up.
The takeaway
Longer follow-up strengthens the case that adding pembrolizumab to enfortumab vedotin can improve survival over chemotherapy in this setting. Patients and clinicians can review the durability of complete responses as more data become available.
Further reading
Explore more coverage in the Cancer section for context on treatment developments.
More information
Read the EV-302 phase 3 abstract on the ASCO website.



